aldesleukin,ict01
imcheck therapeutics,prometheus bio,iovance,novartis
['ict01', 'eviction-2']
johann de bono ( ) is at #aacr23 presenting from 9am edt on the first-in-human study of ict01, an anti-btn3a activating monoclonal antibody in combination with low dose il-2 in patients with advanced #solidtumours (eviction-2 study): #crukfunded
We're here to support our broad cancer research community of 4,000 scientists and clinicians. For general Cancer Research UK news & fundraising follow @CR_UK